FreshPatents.com Logo
Enter keywords:  

Track companies' patents here: Public Companies RSS Feeds | RSS Feed Home Page
Popular terms

[SEARCH]

Immune Disease topics
Immune Disease
Autoimmune
Autoimmune Disease
Immune Diseases
Autoimmune Diseases
Immune Disorder
Transplant
Autoimmune Disorders
Type 1 Diabetes
Autoimmune Disorder
Proliferative Disorder
Signs And Symptoms
Proliferative
Antagonist
Recurrence

Follow us on Twitter
twitter icon@FreshPatents

Web & Computing
Cloud Computing
Ecommerce
Search patents
Smartphone patents
Social Media patents
Video patents
Website patents
Web Server
Android patents
Copyright patents
Database patents
Programming patents
Wearable Computing
Webcam patents

Web Companies
Apple patents
Google patents
Adobe patents
Ebay patents
Oracle patents
Yahoo patents

[SEARCH]

Immune Disease patents



      
           
This page is updated frequently with new Immune Disease-related patent applications. Subscribe to the Immune Disease RSS feed to automatically get the update: related Immune RSS feeds. RSS updates for this page: Immune Disease RSS RSS


Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them

Method and system for prevention and treatment of allergic and inflammatory diseases

Date/App# patent app List of recent Immune Disease-related patents
06/25/15
20150175979
 Ptprs and proteoglycans in autoimmune disease patent thumbnailPtprs and proteoglycans in autoimmune disease
Provided herein, inter alia, are ptprs de-clustering agents and compositions and kits comprising the agents. Provided are methods of modulating extracellular matrix or decreasing fibroblast activity in a subject.
La Jolla Institute For Allergy And Immunology
06/25/15
20150175710
 Alpha-enolase specific antibodies and  use in immune diseases patent thumbnailAlpha-enolase specific antibodies and use in immune diseases
A method for treating an inflammatory disease or an immune disorder includes administering to a subject in need of such treatment an antagonist against eno1. The antagonist binds eno1 and inhibits eno1 plasminogen receptor activity.
Development Center For Biotechnology
06/25/15
20150175623
 Thienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them patent thumbnailThienopyrimidine derivatives, a process for their preparation and pharmaceutical compositions containing them
Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.. .
06/25/15
20150174178
 Method and system for prevention and treatment of allergic and inflammatory diseases patent thumbnailMethod and system for prevention and treatment of allergic and inflammatory diseases
A method and system for exposing an expectant mother to a mixture of farm derived manure-containing soil to reduce the chances her baby will suffer allergies. City dwelling expectant mothers are exposed to immunologic agents and allergens in a fashion (e.g., via exposure to farm animal manure-containing soils) that charges their immune system and that of their fetus(es) so that their babies, once born, are provided with immunity against a variety of autoimmune diseases, including allergies commonly and increasingly experienced in modern urban environments..
06/25/15
20150174090
 Immune tolerance inducer patent thumbnailImmune tolerance inducer
An object of the present invention is to provide a regulatory dendritic cell inducing agent applicable to the treatment of immune disease as well as an immune tolerance inducing agent such as a preventive and/or therapeutic agent for allergic disease and a preventive and/or therapeutic agent for autoimmune disease, both of which are safe and have the mechanism of action different from that of conventional drugs. As a means for achieving the above object, an immune tolerance inducing agent comprising 5-aminolevulinic acid (ala) or a derivative thereof, or a salt of the 5-ala or the derivative and an iron compound as active ingredients is prepared.
National Center For Child Health And Development
06/25/15
20150174063
 Oral administration of tocilizumab treatment of autoimmune disease patent thumbnailOral administration of tocilizumab treatment of autoimmune disease
The present invention provides a method for treating or delaying the onset of an autoimmune condition in a human subject comprising orally administering to the subject at an effective dose of tocilizumab.. .
06/18/15
20150166978
 Apparatus for the extracorporeal treatment of blood patent thumbnailApparatus for the extracorporeal treatment of blood
An apparatus for the extracorporeal treatment of blood comprising an extracorporeal blood circuit (2), a pump (6) configured to provide fluid displacement within the extracorporeal blood circuit, and a reaction chamber (8) connected to the extracorporeal blood circuit and configured to receive blood or plasma from the circuit and treat the blood or plasma. The reaction chamber comprises an protease enzyme immobilized to a support, in which the protease enzyme is specific for, and capable of irreversibly cleaving, a human c5a present in the blood or plasma, wherein the abundance of the human c5a in the treated blood or plasma is less than that in the untreated blood or plasma.
University Of Limerick
06/18/15
20150166658
 Bcr-complex-specific antibodies and methods of using same patent thumbnailBcr-complex-specific antibodies and methods of using same
This invention relates to chimeric and humanized antibodies that specifically bind the bcr complex, and particularly chimeric and humanized antibodies to the bcr complex. The invention also relates to methods of using the antibodies and compositions comprising them in the diagnosis, prognosis and therapy of diseases such as cancer, autoimmune diseases, inflammatory disorders, and infectious disease..
Macrogenics, Inc.
06/18/15
20150165006
 Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen patent thumbnailNucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded allergenic antigen or an autoimmune self-antigen
The present invention relates to a nucleic acid sequence, comprising or coding for a coding region, encoding at least one peptide or protein comprising an allergenic antigen or an autoimmune self-antigen or a fragment, variant or derivative thereof, at least one histone stem-loop and a poly(a) sequence or a polyadenylation signal. Furthermore the present invention provides the use of the nucleic acid for increasing the expression of said encoded peptide or protein.
Cure Gmbh
06/18/15
20150164948
 Acellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases patent thumbnailAcellular pro-tolerogenic compositions for the treatment/prevention of auto-immune diseases
This invention relates to pro-tolerogenic preparations capable of increasing the level of regulatory t cells (treg) and/or decreasing the level of pro-inflammatory t cells (th17) to induce anergy or immune tolerance. The pro-tolerogenic preparation is enriched in at least one species of mirnas and is obtained by contacting two allogeneic leukocyte populations wherein at least one of the two populations is modified with a low-immunogenic biocompatible polymer.
Canadian Blood Services
06/18/15
20150164902

Concentrated methotrexate solutions


Concentrated methotrexate solutions are described which are suitable for the use of an active substance in the production of a parenterally administered medicament for the treatment of inflammatory autoimmune diseases. The methotrexate is added to a pharmaceutically acceptable solvent at a concentration of more than 25 mg/ml..
Medac Gesellschaft Fuer Klinische Spezialpraepararate Mbh
06/18/15
20150164800

Regulating the interaction between tam ligands and lipid membranes with exposed phosphatidyl serine


The present disclosure provides methods for modulating the interaction between a tam ligand and a lipid membrane containing phosphatidyl serine (ptdser). In one example, such methods use a tam receptor agonist having a ptdser-containing lipid bilayer membrane with gas6 and/or protein s bound to the membrane to activate signaling from one or more tam receptors and treat an autoimmune disease.
Salk Institute For Biological Studies
06/11/15
20150158938

Gremlin-1 antibody


The present invention relates to a gremlin-1 antibody that inhibits gremlin-1 in a manner independent of bone morphogenetic protein (bmp) or vascular endothelial growth factor receptor-2 (vegfr-2), thus providing the effect of treating cancer. The antibody of the present invention inhibits cell migration, cell invasion and cell proliferation which are dependent on gremlin-1, and therefore, can be effectively used in treating cancer or immune disease..
Snu R&db Foundation
06/11/15
20150158912

Treatment of il-17 mediated disease by blocking sefir-sefir interactions


A method of treating an il-17 mediated disease in a subject by administering to the subject a therapeutically effective amount of a of a cell-permeable decoy peptide that competitively inhibits binding of the sefir domain of il-17r to the sefir domain of act1. In particular, it has been determined that the αc helix region of the sefir domain of both il-17r and act1 plays an important role in the association of il-17r and act1.
The Cleveland Clinic Foundation
06/11/15
20150158871

Crystalline forms of a bruton's tyrosine kinase inhibitor


Described herein is the bruton's tyrosine kinase (btk) inhibitor 1-((r)-3-(4-amino-3-(4-phenoxyphenyl)-1h-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one, including crystalline forms, solvates and pharmaceutically acceptable salts thereof. Also disclosed are pharmaceutical compositions that include the btk inhibitor, as well as methods of using the btk inhibitor, alone or in combination with other therapeutic agents, for the treatment of autoimmune diseases or conditions, heteroimmune diseases or conditions, cancer, including lymphoma, and inflammatory diseases or conditions..
Pharmacyclics, Inc.
06/11/15
20150158865

Inhibitors of bruton's tyrosine kinase


Disclosed herein are reversible and irreversible inhibitors of bruton's tyrosine kinase (btk). Also disclosed are pharmaceutical compositions that include the compounds.
Pharmacyclics, Inc.
06/11/15
20150158847

Tropomyosin-related kinase (trk) inhibitors


Tropomyosin-related kinase inhibitors (trk inhibitors) are small molecule compounds useful in the treatment of disease. Trk inhibitors can be used as pharmaceutical agents and in pharmaceutical compositions.
Genzyme Corporation
06/04/15
20150152097

Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases


Disclosed are compounds which inhibit the activity of anti-apoptotic bcl-xl proteins, compositions containing the compounds and methods of treating diseases during which is expressed anti-apoptotic bcl-xl protein.. .
Abbvie Inc.
06/04/15
20150150969

Chimeric and humanized anti-histone antibodies


The present invention concerns chimeric or humanized antibodies or antigen-binding fragments thereof that comprise specific cdr sequences, disclosed herein. Preferably, the antibodies or fragments comprise specific heavy and light chain variable region sequences disclosed herein.
Immunomedics, Inc.
06/04/15
20150150956

Epitope composition


A pharmaceutical composition for sublingual, buccal or enteric administration comprising at least one substance obtainable by hydrolysis with chymotrypsin of an antigenic structure which induces graft rejection, allergic reaction or autoimmune disease.. .
Biotech Tools S.a.
06/04/15
20150150951

Pharmaceutical composition comprising bee venom-phospholipase a2 (bv-pla2) for treating or preventing diseases related to degradation of abnormal regulatory t cell activity


The present invention relates to a pharmaceutical composition for treating or preventing a disease related to abnormal suppression of regulatory t cell activity comprising a polypeptide comprising a bee venom-pla2 amino acid sequence exclusive of a leader sequence as an active ingredient. The secretory bee venom-phospholipase a2 of the present invention activates a regulatory t cell and suppress a differentiation of th1/th7.
06/04/15
20150150912

Ceacam1 mediated protective immunity


The presently described technology relates to the modulation of specific immune responses to create a protective immunity in the treatment of autoimmune diseases and diseases requiring the transplantation of tissue. In particular, the present technology relates to the supression of immune responses in a targeted fashion, by increasing the functional concentration of the ceacam1 protein in a target tissue to create a localized protective immunity for the treatment of autoimmune diseases and diseases requiring the transplantation of tissue..
06/04/15
20150150869

Methods and compositions useful for treating diseases involving bcl-2 family proteins with quinoline derivatives


The present invention relates to compositions and methods for cancer treatment comprising compounds of formulae i, ii, and iii. In some aspects, the invention relates to the treatment of b-cell lymphoma or other hematopoietic cancers.
Eutropics Pharmaceuticals, Inc.
05/28/15
20150148413

Desferrioxamine-metal complexes for the treatment of immune-related disorders


The present invention relates to methods kits and combined compositions using dfo-metal complexes, specifically, zinc-desferrioxamine (zn-dfo), gallium-desferrioxamine (ga-dfo) complexes and any combinations thereof for preventing, treating, ameliorating or inhibiting an immune-related disorder, specifically, a skin-related inflammatory disorder such as psoriasis, an inflammatory respiratory condition such as asthma, and an autoimmune disease such as diabetes and any immune-related disorder.. .
Hadasit Medical Research Services And Development Ltd.
05/28/15
20150148361

Benzoimidazol-2-yl pyrimidines and pyrazines as modulators of the histamine h4 receptor


Benzoimidazol-2-yl pyrimidines and pyrazines, pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by h4 receptor activity, including allergy, asthma, autoimmune diseases, and pruritis.. .
Janssen Pharmaceutica Nv
05/28/15
20150148360

3,5,n-trihydroxy-alkanamide and derivatives: making same and use thereof


The present invention provides novel compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) are inhibitors of histone deacetylases (hdacs) and 3-hydroxy-3-methylglutaryl coenzyme a (hmg-coa) reductase (hmgr).
National Taiwan University
05/28/15
20150148331

Melt-extruded solid dispersions containing an apoptosis-inducing agent


A pro-apoptotic solid dispersion comprises, in essentially non-crystalline form, a bcl-2 family protein inhibitory compound of formula i as defined herein, dispersed in a solid matrix that comprises (a) a pharmaceutically acceptable water-soluble polymeric carrier and (b) a pharmaceutically acceptable surfactant. A process for preparing such a solid dispersion comprises subjecting to elevated temperature the compound of formula i, the water-soluble polymeric carrier and the surfactant, to provide an extrudable semi-solid mixture; extruding the semi-solid mixture; and cooling the resulting extrudate to provide a solid matrix comprising the polymeric carrier and the surfactant and having the compound dispersed in essentially non-crystalline form therein.
Abbvie Deutschland Gmbh & Co Kg


Popular terms: [SEARCH]

Immune Disease topics: Immune Disease, Autoimmune, Autoimmune Disease, Immune Diseases, Autoimmune Diseases, Immune Disorder, Transplant, Autoimmune Disorders, Type 1 Diabetes, Autoimmune Disorder, Proliferative Disorder, Signs And Symptoms, Proliferative, Antagonist, Recurrence

Follow us on Twitter
twitter icon@FreshPatents

###

This listing is a sample listing of patent applications related to Immune Disease for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Immune Disease with additional patents listed. Browse our RSS directory or Search for other possible listings.
     SHARE
  
         





0.2774

3960

0 - 1 - 76